Abstract: Viscoelastic hydrogel microparticles are used for repair of tissue defects and injuries or filling and occlusion of anatomical structures. These are administered as a microparticle suspension using a catheter, syringe, steerable catheter tip, or comparable technology into the site, where they can be further stabilized by crosslinking or sealing, or through incorporation of a support or encapsulating structure. Materials and methods for solidifying, stabilizing and sealing these materials can be used that are also biocompatible and easily deployed with catheters in the body. The micron sized interstitial spacing provides a scaffold for ingrowth and migration of cells into the gel matrices.

Abstract: The present invention relates to a method for the production of d-erythro-sphingosine and analogs thereof, wherein the method comprises a step of condensing a compound of formula (2): or a salt thereof, wherein R1 is hydrogen, a C1-50 alkyl, preferably a C1-15 alkyl, more preferably a C10-15 alkyl, which may be saturated or contain one or more double and/or triple bonds, and/or which may contain one or more functional groups, the functional group being preferably selected from the group consisting of an alkoxy group, a secondary, or tertiary amine, a thioether, an acyloxy group, an acylamido group, a phosphorus containing functional group, a carboxyl group, or a carbonyl group, with a compound of formula (3): wherein the bond represents a double or a single bond, W is C, or C(OR4), Z is O, or OR5, provided that: when W is C, the bond is a double bond and Z is O, or when W is C(OR4), the bond is a single bond and Z is OR5, and wherein R2 and R3 are independently selected from a saturate

Abstract: Herein is reported a method for producing a thymocyte supernatant comprising the steps of co-cultivating thymocytes and mononuclear cells at a cell ratio of at least 0.5:1.2 in the presence of phorbol-12-myristate-13-acetate and Phytohemagglutinin M for up to 60 hours, and separating the co-cultivation medium from the cells and thereby producing the thymocyte supernatant.

Abstract: Herein is reported a method for producing a thymocyte supernatant comprising the steps of co-cultivating thymocytes and mononuclear cells at a cell ratio of at least 0.5:1.2 in the presence of phorbol-12-myristate-13-acetate and Phytohemagglutinin M for up to 60 hours, and separating the co-cultivation medium from the cells and thereby producing the thymocyte supernatant.

Abstract: Methods and apparatuses relate to an implantable device for providing contractile assistance to an organ. The device may include an actuator and anchors located on either side of the actuator. The anchors engage with oppositely positioned tissue walls of an organ chamber, and provide contractile assistance to the organ, repeatedly, at appropriate times. For example, the device may be implanted within the right ventricle, anchored to the right ventricular free wall and the ventricular septum. The device may function to bring the opposing walls of the ventricle toward one another, synchronized with the pacing of the heart, resulting in an improved ejection fraction of blood from the chamber. In some embodiments, the actuator includes a bladder that is configured to contract upon receiving an inflow of pressurized fluid therein. When the fluid exits therefrom, the bladder relaxes back to an initial, extended state.

Abstract: Herein is reported a method for producing a thymocyte supernatant comprising the steps of co-cultivating thymocytes and mononuclear cells at a cell ratio of at least 0.5:1.2 in the presence of phorbol-12-myristate-13-acetate and Phytohemagglutinin M for up to 60 hours, and separating the co-cultivation medium from the cells and thereby producing the thymocyte supernatant.

Abstract: Methods and apparatuses relate to an implantable device for providing contractile assistance to an organ. The device may include an actuator and anchors located on either side of the actuator. The anchors engage with oppositely positioned tissue walls of an organ chamber, and provide contractile assistance to the organ, repeatedly, at appropriate times. For example, the device may be implanted within the right ventricle, anchored to the right ventricular free wall and the ventricular septum. The device may function to bring the opposing walls of the ventricle toward one another, synchronized with the pacing of the heart, resulting in an improved ejection fraction of blood from the chamber. In some embodiments, the actuator includes a bladder that is configured to contract upon receiving an inflow of pressurized fluid therein. When the fluid exits therefrom, the bladder relaxes back to an initial, extended state.